TNGX - Tango Therapeutics, Inc.
About Tango Therapeutics, Inc. (https://www.tangotx.com)
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Barbara L. Weber | Founder & Executive Chairman of the Board | 1957 | $1,240,568 USD |
| Adam S. Crystal | President of Research & Development | 1977 | $928,209 USD |
| Daniella Beckman | Executive Officer | 1979 | $765,152 USD |
| Matthew Gall | Chief Financial Officer | 1977 | $717,616 USD |
| Malte Peters | President, Chief Executive Officer & Director | 1962 | $148,315 USD |
| Alan Ashworth | Founder & Member of Scientific Advisory Board | 1961 | – |
| Antoni Ribas | Founder & Member of Scientific Advisory Board | 1967 | – |
| Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications | – | – |
| Jannik N. Andersen | Chief Scientific Officer | – | – |
| Julie Carretero | Chief Human Resources Officer | 1973 | – |
| Julie Fogarty | Vice President of Legal & Corporate Secretary | – | – |
| Philippe Serrano | Chief Regulatory Officer | – | – |
| William G. Kaelin Jr. | Founder & Member of Scientific Advisory Board | 1958 | – |